EA201491614A1 - Способ лечения гинекологических заболеваний - Google Patents

Способ лечения гинекологических заболеваний

Info

Publication number
EA201491614A1
EA201491614A1 EA201491614A EA201491614A EA201491614A1 EA 201491614 A1 EA201491614 A1 EA 201491614A1 EA 201491614 A EA201491614 A EA 201491614A EA 201491614 A EA201491614 A EA 201491614A EA 201491614 A1 EA201491614 A1 EA 201491614A1
Authority
EA
Eurasian Patent Office
Prior art keywords
gynecological diseases
treating gynecological
pharmaceutical composition
receptor modulator
progesterone receptor
Prior art date
Application number
EA201491614A
Other languages
English (en)
Other versions
EA031488B1 (ru
Inventor
Жан-Пьер Готтеланд
Валери Бужак
Эрнест Луме
Original Assignee
Преглем Са
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Преглем Са filed Critical Преглем Са
Publication of EA201491614A1 publication Critical patent/EA201491614A1/ru
Publication of EA031488B1 publication Critical patent/EA031488B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение относится главным образом к комбинации для применения при лечении гинекологических заболеваний и сопутствующих им инвалидизирующих симптомов у субъекта, нуждающегося в этом, где фармацевтическая комбинация для применения включает в себя совместное введение подходящей фармацевтической композиции для перорального приема, содержащей первый модулятор прогестероновых рецепторов, и фармацевтической композиции, пригодной для вагинального и/или внутриматочного введения, содержащей второй модулятор прогестероновых рецепторов.
EA201491614A 2012-03-23 2013-03-22 Способ лечения гинекологических заболеваний EA031488B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261614785P 2012-03-23 2012-03-23
EP12160956.4A EP2641602A1 (en) 2012-03-23 2012-03-23 Method for treating gynecological diseases
PCT/IB2013/052274 WO2013140372A1 (en) 2012-03-23 2013-03-22 Method for treating gynecological diseases

Publications (2)

Publication Number Publication Date
EA201491614A1 true EA201491614A1 (ru) 2015-01-30
EA031488B1 EA031488B1 (ru) 2019-01-31

Family

ID=45976689

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491614A EA031488B1 (ru) 2012-03-23 2013-03-22 Способ лечения гинекологических заболеваний

Country Status (18)

Country Link
US (1) US10441534B2 (ru)
EP (3) EP2641602A1 (ru)
JP (2) JP2015514700A (ru)
KR (1) KR20140138824A (ru)
CN (1) CN104203246A (ru)
AU (1) AU2013236960B2 (ru)
CA (1) CA2864073A1 (ru)
CO (1) CO7111317A2 (ru)
EA (1) EA031488B1 (ru)
GE (1) GEP201706696B (ru)
HK (1) HK1199827A1 (ru)
MX (1) MX369520B (ru)
MY (1) MY172530A (ru)
NZ (1) NZ630011A (ru)
SG (1) SG11201404921QA (ru)
TW (2) TW201832767A (ru)
WO (1) WO2013140372A1 (ru)
ZA (1) ZA201407575B (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11110103B2 (en) 2015-12-23 2021-09-07 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
CN108699102A (zh) 2015-12-23 2018-10-23 欧瑞克制药公司 糖皮质激素受体抑制剂
CA3009525A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
WO2017165707A1 (en) * 2016-03-24 2017-09-28 Juniper Pharmaceuticals, Inc. Vaginal administration of agents for treating and preventing pain associated with gynecological medical procedures
EP3851444A1 (en) 2016-10-07 2021-07-21 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3545439A (en) 1968-01-04 1970-12-08 Upjohn Co Medicated devices and methods
US3920805A (en) 1971-12-09 1975-11-18 Upjohn Co Pharmaceutical devices and method
US4155991A (en) 1974-10-18 1979-05-22 Schering Aktiengesellschaft Vaginal ring
IL48277A (en) 1974-10-18 1978-03-10 Schering Ag Vaginal ring
US3995633A (en) 1975-12-02 1976-12-07 The Procter & Gamble Company Vaginal Medicament dispensing device
US3995634A (en) 1975-12-02 1976-12-07 The Procter & Gamble Company Vaginal cavity dispensing means and method
US3991760A (en) 1975-12-02 1976-11-16 The Procter & Gamble Company Vaginal medicament dispensing means
US4286587A (en) 1978-10-11 1981-09-01 Alza Corporation Vaginal drug delivery system made from polymer
US4292965A (en) 1978-12-29 1981-10-06 The Population Council, Inc. Intravaginal ring
US4250611A (en) 1979-04-19 1981-02-17 Alza Corporation Process for making drug delivery device with reservoir
EP0180264A1 (en) 1984-10-12 1986-05-07 Akzo N.V. Release system for two or more active substances
NL8500470A (nl) 1985-02-19 1986-09-16 Achel Homesteel Pvba Intravaginaal orgaan.
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
FI95768C (fi) 1993-06-17 1996-03-25 Leiras Oy Emättimensisäinen antosysteemi
US5929262A (en) 1995-03-30 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates
US5972372A (en) 1996-07-31 1999-10-26 The Population Council, Inc. Intravaginal rings with insertable drug-containing core
ES2212912B1 (es) 2003-01-22 2005-10-01 Crystal Pharma, S.A. Procedimiento para la obtencion de 17alfa-acetoxi-11beta-(4-n,n-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona.
CA2516319C (en) 2003-02-28 2012-09-18 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Method for preparing 17.alpha.-acetoxy-11.beta.-(4-n,n-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, intermediates thereof, and methods for the preparation of such intermediates
MX2007000273A (es) 2004-07-09 2007-05-21 Population Council Inc Composiciones de liberacion sostenida que contiene moduladores del receptor de progesterona.
EP2148681B1 (en) * 2007-04-20 2016-03-16 PregLem S.A. Selective progesterone modulators in the treatment of uterine bleeding
US8299050B2 (en) * 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids
BRPI0905946B8 (pt) * 2008-02-04 2021-05-25 Ferring Bv anel intravaginal monolítico e processo para a produção de um anel intravaginal monolítico

Also Published As

Publication number Publication date
GEP201706696B (en) 2017-07-10
AU2013236960A1 (en) 2014-09-25
MX2014011487A (es) 2015-01-12
CO7111317A2 (es) 2014-11-10
SG11201404921QA (en) 2014-10-30
EP3363500A1 (en) 2018-08-22
HK1199827A1 (en) 2015-07-24
TW201832767A (zh) 2018-09-16
CA2864073A1 (en) 2013-09-26
US20150038476A1 (en) 2015-02-05
AU2013236960B2 (en) 2017-11-23
KR20140138824A (ko) 2014-12-04
JP2015514700A (ja) 2015-05-21
EA031488B1 (ru) 2019-01-31
JP2018109025A (ja) 2018-07-12
WO2013140372A1 (en) 2013-09-26
MY172530A (en) 2019-11-29
US10441534B2 (en) 2019-10-15
TW201400121A (zh) 2014-01-01
MX369520B (es) 2019-11-11
NZ630011A (en) 2016-12-23
CN104203246A (zh) 2014-12-10
EP2641602A1 (en) 2013-09-25
EP2827873A1 (en) 2015-01-28
ZA201407575B (en) 2015-12-23

Similar Documents

Publication Publication Date Title
UA112288C2 (uk) Склад антитіла, що специфічно зв'язує рецептор а іl-17, і терапевтичні режими
MX2019003467A (es) Formulaciones y metodos para la administracion vaginal de antiprogestinas.
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
AR092177A1 (es) Metodos para tratar o prevenir asma administrando un antagonista de il-4r
MY174727A (en) Stable, protracted glp-1/glucagon receptor co-agonists for medical use
EA201991484A1 (ru) Лекарственные формы энзалутамида
WO2015085143A3 (en) Therapeutic agents for skin diseases and conditions
PH12015500246A1 (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
EA201290171A1 (ru) Вводимые перорально кортикостероидные композиции
NZ606993A (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
EP2381957A4 (en) THERAPEUTIC MODULATION OF VAGINAL EPITHELIUM LIMITING LUBRICATION
NZ606765A (en) Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
EA201491614A1 (ru) Способ лечения гинекологических заболеваний
MX2014000066A (es) Formulaciones mucoadhesivas en gel de alta dosificación de metronidazol de base acuosa y su uso para tratar la vaginosis bacteriana.
EA201390417A1 (ru) Антидиабетические твердые фармацевтические композиции
MX2015005993A (es) Composiciones y metodos para el tratamiento de displasia ectodermica.
EA201591603A1 (ru) Новые терапевтические комбинации миртазапина для применения при болевых расстройствах
CL2015003014A1 (es) Composición farmacéutica que comprende 0,5-5 mg de (11?,17?)-17-hidroxi-11-[4-(metilsulfonil)fenil]-17-(pentafluoroetil)estra-4,9-dien-3-ona; forma de dosificación oral; uso para tratar y/o prevenir una enfermedad ginecológica, tal como, fibroides en el útero, endometriosis o hemorragias menstruales excesivas.
UA112981C2 (uk) Варіант людського gdnf
MX2016006375A (es) Una combinacion de unidades de dosificacion para su uso en el tratamiento del parto prematuro.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU